Skip to content

Clinical trials on the efficacy and safety of nobiletin aminoplus for urine storage disorders

Clinical trial of nobiletin aminoplus for urine storage disorders - Nobiletin Amino Plus Clinical Trials

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000046969
Enrollment
70
Registered
2022-02-22
Start date
2021-11-18
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urine storage disorders

Interventions

The dosage form is Nobiletin Amino Plus (50 mg of Nobiletin PMF90 containing 30 mg of Nobiletin and 15 mg of Tangeretin plus 3 g of glycine). Administration should be once daily in the morning and con

Sponsors

Okinawa Aloe Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Untreated adult volunteers who have had frequent urination, nocturia, urinary urgency, or urge incontinence for more than 2 months and have some trouble with it, but have not been treated.

Exclusion criteria

Exclusion criteria: 1. Those who are treating micturition disorders 2. Foods for specified health use, health foods and supplements related to urination and sleep, energy drinks, shikuwasa drinks, etc. are taken daily or frequently. 3. Those within 2 months from the end of treatment for micturition disorders 4. Those who have no urge to urinate 5. Difficulty urinating is the main symptom 6. Those who are allergic to food or drugs 7. Things that are difficult to communicate with 8. Others that the doctor in charge judged inappropriate for registration in this study

Design outcomes

Primary

MeasureTime frame
Overactive bladder symptom score

Secondary

MeasureTime frame
Number of urination during the day and night, international prostate symptom score

Countries

Japan

Contacts

Public ContactKimio Sugaya

Southern Knights' Laboratory Co., Ltd. CEO

sugaya@sklabo.co.jp090-4998-7459

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026